Depression and Anxiety Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older at the time of enrolling in the study
- People who are able to understand the study and agree to take part
- People who speak and read English fluently
- People who are willing to have their coaching sessions recorded using an approved, privacy-protected video platform
- People whose depression symptom score (measured by a questionnaire called the QIDS-SR) is at a moderate or higher level at the screening visit
- People who have been diagnosed with a depressive disorder at some point in their lifetime, confirmed using a structured clinical interview called the MINI
- People who are in the ongoing maintenance phase of ketamine or esketamine treatment, meaning they have already completed the initial intensive treatment course
- People who have completed at least 3 maintenance treatments before the screening visit, and whose QIDS-SR scores from those 3 most recent treatments show at least moderate depression severity
- People who are currently receiving maintenance ketamine (given through a drip) or esketamine (given as a nasal spray) at the MGH Ketamine Clinic, have had at least one treatment in the past 8 weeks, and plan to continue as an active patient there for the full duration of the study
- People who already have an established relationship with a mental health provider (such as a psychiatrist or therapist), and who agree to sign a release of information form if that provider is outside the Mass General Brigham healthcare system
Who may not be able to join:
- People with an unstable medical condition, as determined by the study clinician
- People with significant cognitive difficulties that affect their ability to carry out daily activities and would interfere with taking part in the study, as judged by the study clinician
- People who have started a new course of psychotherapy within the past 3 months
- People whose situation or circumstances make participation unsafe or unsuitable, in the judgment of the Principal Investigator
- People with a psychiatric condition other than depression that is currently the main or most significant concern, or that is not sufficiently stable, and would interfere with study participation, as judged by the study clinician
- People who are planning to switch between IV ketamine and intranasal esketamine (or vice versa) at any point during the study
- People assessed by the study clinicians as having current thoughts of suicide with a plan to act within the next 6 months
- People whose depression symptom score improves by 25% or more between the screening visit and the baseline visit
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Maren Nyer, PhD, Massachusetts General Hospital and Harvard Medical School
Phone: 6176434897
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To assess the feasibility of adjunctive coaching during ketamine/esketamine maintenance treatment.; To assess the acceptability of adjunctive coaching during ketamine/esketamine maintenance treatment.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.